With CRO con­sol­i­da­tion in full swing, Catal­ent inks a $950M deal to ac­quire Cook Pharmi­ca and sig­nals an ap­petite for more

To­day it is Catal­ent’s turn to take a lead role in the con­sol­i­da­tion of the glob­al out­sourc­ing busi­ness.

The big and grow­ing CMO has snapped up Bloom­ing­ton, IN-based Cook Pharmi­ca for $950 mil­lion, adding a group with 750 staffers in­volved in bi­o­log­ics de­vel­op­ment and bio­man­u­fac­tur­ing and flesh­ing out the start-to-fin­ish suite of ser­vices that Catal­ent has on of­fer to the bio­phar­ma world.

Cook is bring­ing their 875,000 square foot fa­cil­i­ty in Bloom­ing­ton to the Catal­ent or­ga­ni­za­tion, along with an­nu­al rev­enue of $179 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.